This Morning's Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec Medical

NEW YORK, Feb. 15, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on NLNK, OHRP, OMER, and ONCS which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com scans NewLink Genetics Corp. (NASDAQ: NLNK), OHR Pharmaceutical Inc. (NASDAQ: OHRP), Omeros Corp. (NASDAQ: OMER), and OncoSec Medical Inc. (NASDAQ: ONCS). These stocks are part of the Biotech space, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include Medical, Agricultural, Environmental, and Industrial. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

NewLink Genetics

On Wednesday, shares in Ames, Iowa headquartered NewLink Genetics Corp. recorded a trading volume of 1.06 million shares, which was higher than their three months average volume of 841.39 thousand shares. The stock ended at $6.77, rising 3.20% from the last trading session. The stock is trading below its 50-day moving average by 18.60%. Furthermore, shares of NewLink Genetics, which focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer, have a Relative Strength Index (RSI) of 34.52. Get the full research report on NLNK for free by clicking below at:

www.wallstequities.com/registration/?symbol=NLNK

OHR Pharmaceutical

New York headquartered OHR Pharmaceutical Inc.'s stock finished yesterday's session 1.20% lower at $0.31. A total volume of 1.24 million shares was traded. The stock is trading below its 50-day moving average by 66.32%. Furthermore, shares of OHR Pharma, which focuses on the development of novel therapies for the treatment of ophthalmic diseases, have an RSI of 28.67. OHRP's complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=OHRP

Omeros

At the close of trading on Wednesday, shares in Seattle, Washington-based Omeros Corp. saw a decline of 17.58%, ending the day at $11.25. The stock recorded a trading volume of 5.69 million shares, which was higher than its three months average volume of 681.75 thousand shares. The Company's shares have advanced 0.36% over the last twelve months. The stock is trading below its 50-day moving average by 37.92%. Moreover, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 18.05. Register for your free research report on OMER at:

www.wallstequities.com/registration/?symbol=OMER

OncoSec Medical

San Diego, California headquartered OncoSec Medical Inc.'s shares ended the day 3.72% higher at $1.95 with a total trading volume of 938,099 shares. The stock has gained 36.36% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 7.03% and 45.55%, respectively. Additionally, shares of OncoSec Medical, which designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the US, have an RSI of 56.73.

On February 09^th, 2018, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock, with a target price of $4 per share. Wall St. Equities' downloadable research report on ONCS available at:

www.wallstequities.com/registration/?symbol=ONCS

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities

Related Links

http://www.wallstequities.com